Welcome to our dedicated page for Prothena news (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena stock.
Prothena Corporation plc develops investigational therapeutics built on protein dysregulation expertise for neurodegenerative and rare peripheral amyloid diseases. Company news commonly covers clinical and partner updates for programs such as prasinezumab in Parkinson’s disease, coramitug in ATTR amyloidosis with cardiomyopathy, BMS-986446 in Alzheimer’s disease, PRX019, and CYTOPE-based research.
Updates also include financial results, cash guidance, collaboration revenue and milestone payments from strategic partners, regulatory designations, share repurchase activity, shareholder capital actions, and leadership or governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Prothena Corporation plc (NASDAQ:PRTA), a clinical biotechnology firm, announced its participation in a fireside chat at the 2023 Bank of America Healthcare Conference in Las Vegas on May 9, 2023, at 9:20 AM PT. This event will showcase insights from the company’s senior management regarding their investigational therapeutics pipeline, focusing on protein dysregulation and neurodegenerative diseases. A live webcast of the chat will be available on Prothena's investor relations website, with a replay accessible for 90 days afterward. Prothena specializes in developing treatments for conditions like AL amyloidosis, ATTR amyloidosis, Alzheimer’s, and Parkinson’s diseases, positioning itself as a key player in addressing these pressing health challenges.
Walgreens and Prothena have announced a collaboration to enhance patient recruitment for Prothena's PRX012, a potential Alzheimer’s treatment currently in the ASCENT-2 clinical trial. Walgreens will utilize its extensive network and healthcare capabilities to identify suitable candidates, focusing on underserved communities. This trial has received Fast Track designation from the FDA, indicating its potential significance in addressing Alzheimer’s disease, which affects over 6.5 million Americans aged 65 and older. The partnership aims to create a more diverse patient population for the trial, aligning with the ENACT Act to improve inclusivity in Alzheimer’s research. Key topline data from ongoing Phase 1 studies is expected by the end of 2023.